Published in New England Journal of Medicine · View the paper (DOI)
Researchers have identified a new therapeutic option for patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease. Benralizumab has been shown to be non-inferior to mepolizumab in reducing exacerbations and providing disease remission, with the added benefit of reduced oral corticosteroid use.
Coverage from 2 institutions